Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-23T08:36:59.614Z Has data issue: false hasContentIssue false
  • English
  • Français

Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study

Published online by Cambridge University Press:  25 October 2016

S. R. T. Veerman ,
P. F. J. Schulte ,
J. B. Deijen  and
L. de Haan
S. R. T. Veerman*
Affiliation:
Mental Health Service Noord-Holland Noord, Community Mental Health Division, Flexible Assertive Community Treatment, Alkmaar, The Netherlands
P. F. J. Schulte
Affiliation:
Mental Health Service Noord-Holland Noord, Division for Specialized Treatment, Treatment Centre for Bipolar Disorders, Alkmaar, The Netherlands
J. B. Deijen
Affiliation:
Vrije Universiteit, Faculty of Behavioural and Movement Sciences, Section Clinical Neuropsychology, Amsterdam, The Netherlands
L. de Haan
Affiliation:
Early Psychosis Department, Academic Medical Centre, University of Amsterdam, Academic Psychiatric Centre, Arkin, Amsterdam, The Netherlands
*
*Address for correspondence: S. R. T. Veerman, M.D., Mental Health Service Noord-Holland Noord, Community Mental Health Division, Flexible Assertive Community Treatment, Oude Hoeverweg 10, 1816 BT Alkmaar, The Netherlands. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

In a recent placebo-controlled, double-blind crossover trial (n = 52), significant beneficial effects on memory (d = 0.30) and negative symptoms (d = 0.29) were found after 12 weeks of memantine augmentation in patients with clozapine-refractory schizophrenia. In this open-label 1-year extension study we report the long-term effects and tolerability of memantine add-on therapy to clozapine.

Method

Completers of the first trial who experienced beneficial effects during 12 weeks of memantine treatment received memantine for 1 year. Primary endpoints were memory and executive function using the Cambridge Neuropsychological Test Automated Battery, the Positive and Negative Syndrome Scale (PANSS), and the Clinical Global Impression Severity Scale (CGI-S).

Results

Of 31 randomized controlled trial completers who experienced beneficial effects from memantine, 24 received memantine for 1 year. The small improvement in memory found in the memantine condition in the placebo-controlled trial remained stable in the extension study. Executive function did not improve. After 26 weeks of memantine add-on therapy to clozapine, PANSS negative symptoms (r = 0.53), PANSS positive symptoms (r = 0.50) and PANSS total symptoms (r = 0.54) significantly improved. Even further significant improvement in all these measures was observed between 26 weeks and 52 weeks of memantine, with effect sizes varying from 0.39 to 0.51. CGI-S showed a non-significant moderate improvement at 26 weeks (r = 0.36) and 52 weeks (r = 0.34). Memantine was well tolerated without serious adverse effects.

Conclusions

In the 1-year extension phase the favourable effect of adjunctive memantine on memory was sustained and we observed further improvement of negative, positive and overall symptoms in patients with clozapine-treated refractory schizophrenia.

Keywords

Clozapinecognitive functioningglutamate antagonistsmemantinetherapy-resistant schizophrenia
Type
Original Articles
Information
Psychological Medicine , Volume 47 , Issue 2 , January 2017 , pp. 363 - 375
Copyright
Copyright © Cambridge University Press 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addington, D, Addington, J, Schissel, B (1990). A depression rating scale for schizophrenics. Schizophrenia Research 3, 247–251.CrossRefGoogle ScholarPubMed
Agid, O, Foussias, G, Singh, S, Remington, G (2010). Where to position clozapine: re-examining the evidence. Canadian Journal of Psychiatry 55, 677–684.CrossRefGoogle ScholarPubMed
Anderson, VM, McIlwain, ME, Kydd, RR, Russell, BR (2015). Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders? Psychiatry Research 230, 811–818.CrossRefGoogle ScholarPubMed
Andreasen, NC, Carpenter, WT Jr., Kane, JM, Lasser, RA, Marder, SR, Weinberger, DR (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry 162, 441–449.CrossRefGoogle ScholarPubMed
Areosa, SA, Sherriff, F (2003). Memantine for dementia. Cochrane Database of Systematic Reviews, issue 3, CD003154.CrossRefGoogle ScholarPubMed
Barnett, JH, Robbins, TW, Leeson, VC, Sahakian, BJ, Joyce, EM, Blackwell, AD (2010). Assessing cognitive function in clinical trials of schizophrenia. Neuroscience and Biobehavioral Reviews 34, 1161–1177.CrossRefGoogle ScholarPubMed
Baron-Cohen, S, Jolliffe, T, Mortimore, C, Robertson, M (1997). Another advanced test of theory of mind: evidence from very high-functioning adults with autism or Asperger syndrome. Journal of Child Psychology and Psychiatry 38, 813–822.CrossRefGoogle ScholarPubMed
Beglinger, LJ, Ahmed, S, Derby, MA, Siemers, E, Fastenau, PS, Crawford-Miller, J, Shekhar, A, Kareken, DA (2003). Neuropsychological practice effects and change detection in people with schizophrenia. Schizophrenia Research 62, 191–194.CrossRefGoogle ScholarPubMed
Beister, A, Kraus, P, Kuhn, W, Dose, M, Weindl, A, Gerlach, M (2004). The N-methyl-d-aspartate antagonist memantine retards progression of Huntington's disease. Journal of Neural Transmission 68, 117–122.CrossRefGoogle Scholar
Bourque, J, Lakis, N, Champagne, J, Stip, E, Lalonde, P, Lipp, O, Mendrek, A (2013). Clozapine and visuospatial processing in treatment-resistant schizophrenia. Cognitive Neuropsychiatry 18, 615–630.CrossRefGoogle ScholarPubMed
Buchanan, RW, Davis, M, Goff, D, Green, MF, Keefe, RS, Leon, AC, Nuechterlein, KH, Laughren, T, Levin, R, Stover, E, Fenton, W, Marder, SR (2005). A summary of the FDA–NIMH MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophrenia Bulletin 31, 5–19.CrossRefGoogle ScholarPubMed
Buckley, P, Miller, A, Olsen, J, Garver, D, Miller, DD, Csernansky, J (2001). When symptoms persist: clozapine augmentation strategies. Schizophrenia Bulletin 27, 615–628.CrossRefGoogle ScholarPubMed
Cerullo, MA, Adler, CM, Strakowski, SM, Eliassen, JC, Nasrallah, HA, Nasrallah, AT (2007). Memantine normalizes brain activity in the inferior frontal gyrus: a controlled pilot fMRI study. Schizophrenia Research 97, 294–296.CrossRefGoogle ScholarPubMed
Chatfield, M, Mander, A (2009). The Skillings–Mack test (Friedman test when there are missing data). Stata Journal 9, 299–305.CrossRefGoogle ScholarPubMed
Crow, R, Cage, H, Hampson, S, Hart, J, Kimber, A, Thomas, H (1999). The role of expectancies in the placebo effect and their use in the delivery of health care: a systematic review. Health Technology Assessment 3, 1–96.CrossRefGoogle ScholarPubMed
Day, JC, Wood, G, Dewey, M, Bentall, RP (1995). A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. British Journal of Psychiatry 166, 650–653.CrossRefGoogle Scholar
de Bartolomeis, A, Balletta, R, Giordano, S, Buonaguro, EF, Latte, G, Iasevoli, F (2013). Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Research 210, 387–395.CrossRefGoogle Scholar
de la Fuente-Sandoval, C, Reyes-Madrigal, F, Mao, X, León-Ortiz, P, Rodríguez-Mayoral, O, Solís-Vivanco, R, Favila, R, Graff-Guerrero, A, Shungu, DC (2015). Cortico-striatal GABAergic and glutamatergic dysregulations in subjects at ultra-high risk for psychosis investigated with proton magnetic resonance spectroscopy. International Journal of Neuropsychopharmacology 19, pyv105.CrossRefGoogle ScholarPubMed
de Lucena, D, Fernandes, BS, Berk, M, Dodd, S, Medeiros, DW, Pedrini, M, Kunz, M, Gomes, FA, Giglio, LF, Lobato, MI, Belmonte-de-Abreu, PS, Gama, CS (2009). Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. Journal of Clinical Psychiatry 70, 1416–1423.CrossRefGoogle ScholarPubMed
Demjaha, A, Egerton, A, Murray, RM, Kapur, S, Howes, OD, Stone, JM, McGuire, PK (2014). Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biological Psychiatry 75, e11–e13.CrossRefGoogle ScholarPubMed
Demjaha, A, Murray, RM, McGuire, PK, Kapur, S, Howes, OD (2012). Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. American Journal of Psychiatry 169, 1203–1210.CrossRefGoogle ScholarPubMed
Elkis, H (2007). Treatment-resistant schizophrenia. Psychiatric Clinics of North America 30, 511–533.CrossRefGoogle ScholarPubMed
Ferguson, JM, Shingleton, RN (2007). An open-label, flexible-dose study of memantine in major depressive disorder. Clinical Neuropharmacology 30, 136–144.CrossRefGoogle ScholarPubMed
Fisher, S, Greenberg, RP (1993). How sound is the double-blind design for evaluating psychotropic drugs? Journal of Nervous and Mental Disease 181, 345–350.CrossRefGoogle ScholarPubMed
Fletcher, PC, McKenna, PJ, Frith, CD, Grasby, PM, Friston, KJ, Dolan, RJ (1998). Brain activations in schizophrenia during a graded memory task studied with functional neuroimaging. Archives of General Psychiatry 55, 1001–1008.CrossRefGoogle ScholarPubMed
Frydecka, D, Beszlej, JA, Gościmski, P, Kiejna, A, Misiak, B (2016). Profiling cognitive impairment in treatment-resistant schizophrenia patients. Psychiatry Research 235, 133–138.CrossRefGoogle ScholarPubMed
Gameiro, Z, Esteves, H (2015). Should we use memantine in obsessive–compulsive disorder? European Psychiatry 30, 1502.CrossRefGoogle Scholar
Glodzik, L, King, KG, Gonen, O, Liu, S, De Santi, S, de Leon, MJ (2008). Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32, 1005–1012.CrossRefGoogle Scholar
Goodman, WK, Price, LH, Rasmussen, SA, Mazure, C, Delgado, P, Heninger, GR, Charney, DS (1989). The Yale–Brown Obsessive Compulsive Scale. Archives of General Psychiatry 46, 1012–1016.CrossRefGoogle ScholarPubMed
Guy, W (1976). Clinical Global Impression Scale. In ECDEU Assessment Manual for Psychopharmacology-Revised, pp. 218–222. US Department of Health, Education and Welfare, ADAMHA, NIMH Psychopharmacology Research Branch: Rockville, MD.Google Scholar
Holm, S (1979). A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics 6, 65–70.Google Scholar
Howes, OD, Kapur, S (2014). A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). British Journal of Psychiatry 205, 1–3.CrossRefGoogle ScholarPubMed
Kahn, RS, Sommer, IE (2015). The neurobiology and treatment of first-episode schizophrenia. Molecular Psychiatry 20, 84–97.CrossRefGoogle ScholarPubMed
Kay, SR, Fiszbein, A, Opler, LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261–276.CrossRefGoogle ScholarPubMed
Keefe, RS, Buchanan, RW, Marder, SR, Schooler, NR, Dugar, A, Zivkov, M, Stewart, M (2013). Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophrenia Bulletin 39, 417–435.CrossRefGoogle ScholarPubMed
Kegeles, LS, Mao, X, Stanford, AD, Girgis, R, Ojeil, N, Xu, X, Gil, R, Slifstein, M, Abi-Dargham, A, Lisanby, SH, Shungu, DC (2012). Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Archives of General Psychiatry 69, 449–459.Google ScholarPubMed
Kinon, BJ, Potts, AJ, Watson, SB (2011). Placebo response in clinical trials with schizophrenia patients. Current Opinion in Psychiatry 24, 107–113.Google ScholarPubMed
Lawrence, NS, Ross, TJ, Hoffmann, R, Garavan, H, Stein, EA (2003). Multiple neuronal networks mediate sustained attention. Journal of Cognitive Neuroscience 15, 1028–1038.CrossRefGoogle ScholarPubMed
Lawrie, SM, O'Donovan, MC, Saks, E, Burns, T, Lieberman, JA (2016). Towards diagnostic markers for the psychoses. Lancet Psychiatry 3, 375–385.CrossRefGoogle ScholarPubMed
Levaux, MN, Potvin, S, Sepehry, AA, Sablier, J, Mendrek, A, Stip, E (2007). Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. European Psychiatry 22, 104–115.CrossRefGoogle ScholarPubMed
Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Orey, D, Richter, F, Samara, M, Barbui, C, Engel, RR, Geddes, JR, Kissling, W, Stapf, MP, Lässig, B, Salanti, G, Davis, JM (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382, 951–962.CrossRefGoogle ScholarPubMed
Liemburg, E, Catelein, S, Stewart, R, van der Gaag, M, Aleman, A, Knegtering, H; Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2013). Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. Journal of Psychiatric Research 47, 718–725.CrossRefGoogle ScholarPubMed
Lowe, C, Rabbitt, P (1998). Test/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues. Cambridge Neuropsychological Test Automated Battery. International Study of Post-Operative Cognitive Dysfunction. Neuropsychologia 36, 915–923.CrossRefGoogle Scholar
McShane, R, Areosa, SA, Minakaran, N (2006). Memantine for dementia. Cochrane Database of Systematic Reviews, issue 2, CD003154.CrossRefGoogle ScholarPubMed
Mouchlianitis, E, Bloomfield, MA, Law, V, Beck, K, Selvaraj, S, Rasquinha, N, Waldman, A, Turkheimer, FE, Egerton, A, Stone, J, Howes, OD (2015). Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophrenia Bulletin 24, 744–752.Google Scholar
Mukaka, MM (2012). A guide to appropriate use of correlation coefficient in medical research. Malawi Medical Journal 24, 69–71.Google ScholarPubMed
Nuechterlein, KH, Green, MF, Kern, RS, Baade, LE, Barch, DM, Cohen, JD, Essock, S, Fenton, WS, Frese, FJ III, Gold, JM, Goldberg, T, Heaton, RK, Keefe, RS, Kraemer, H, Mesholam-Gately, R, Seidman, LJ, Stover, E, Weinberger, DR, Young, AS, Zalcman, S, Marder, SR (2008). The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability and validity. American Journal of Psychiatry 165, 203–213.CrossRefGoogle ScholarPubMed
Overbeek, T, Schruers, K, Griez, E (1999). MINI. Mini International Neuropsychiatric Interview. Dutch version 5.0.0. DSM-IV. University of Maastricht: Maastricht, The Netherlands.Google Scholar
Priebe, S, Huxley, P, Knight, S, Evans, S (1999). Application and results of the Manchester Short Assessment of Quality of Life (MANSA). International Journal of Social Psychiatry 45, 7–12.CrossRefGoogle ScholarPubMed
Sackett, DL (1979). Bias in analytic research. Journal of Chronic Disease 32, 51–63.CrossRefGoogle ScholarPubMed
Sani, G, Serra, G, Kotzalidis, GD, Romano, S, Tamorri, SM, Manfredi, G, Caloro, M, Telesforo, CL, Caltagirone, SS, Panaccione, I, Simonetti, A, Demontis, F, Serra, G, Girardi, P (2012). The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. Central Nervous System Drugs 26, 663–690.Google Scholar
Schifitto, G, Navia, BA, Yiannoutsos, CT, Marra, CM, Chang, L, Ernst, T, Jarvik, JG, Miller, EN, Singer, EJ, Ellis, RJ, Kolson, DL, Simpson, D, Nath, A, Berger, J, Shriver, SL, Millar, LL, Colguhoun, D, Lenkinski, R, Gonzalez, RG, Lipton, SA; Adult AIDS Clinical Trial Group (ACTG) 301; 700 Teams; HIV MRS Consortium (2007). Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 21, 1877–1886.CrossRefGoogle ScholarPubMed
Schwenkreis, P, Witscher, K, Pleger, B, Malin, JP, Tegenthoff, M (2005). The NMDA antagonist memantine affects training induced motor cortex plasticity – a study using transcranial magnetic stimulation. BMC Neuroscience 6, 35.CrossRefGoogle ScholarPubMed
Thermenos, HW, Goldstein, JM, Buka, SL, Poldrack, RA, Koch, JK, Tsuang, MT, Seidman, LJ (2005). The effect of working memory performance on functional MRI in schizophrenia. Schizophrenia Research 74, 179–194.CrossRefGoogle ScholarPubMed
Tomasi, D, Ernst, T, Caparelli, EC, Chang, L (2006). Common deactivation patterns during working memory and visual attention tasks: an intra-subject fMRI study at 4 Tesla. Human Brain Mapping 27, 694–705.CrossRefGoogle Scholar
Tomczak, M, Tomczak, E (2014). The need to report effect size estimates revisited. An overview of some recommended measures of effect size. Trends in Sport Sciences 21, 19–25.Google Scholar
van der Gaag, M, Hoffman, T, Remijsen, M, Hijman, R, de Haan, L, van Meijel, B, van Harten, PN, Valmaggia, L, de Hert, M, Cuijpers, A, Wiersma, D (2006). The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophrenia Research 85, 280–287.CrossRefGoogle Scholar
van Veldhuizen, JR (2007). FACT: a Dutch version of ACT. Community Mental Health Journal 43, 421–433.CrossRefGoogle ScholarPubMed
Veerman, SRT, Schulte, PF, Begemann, MJ, Engelsbel, F, de Haan, L (2014 a). Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis. Pharmacopsychiatry 47, 185–194.Google ScholarPubMed
Veerman, SRT, Schulte, PF, de Haan, L (2014 b). The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. Pharmacopsychiatry 47, 121–130.Google ScholarPubMed
Veerman, SRT, Schulte, PF, Smith, JD, de Haan, L (2016). Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Psychological Medicine 46, 1909–1921.CrossRefGoogle ScholarPubMed
Wesemann, W, Sontag, KH, Maj, J (1983). Pharmacodynamics and pharmacokinetics of memantine. Arzniemittelforschung 33, 1122–1134.Google ScholarPubMed
Wiech, K, Kiefer, RT, Töpfner, S, Preiss, H, Braun, C, Unertl, K, Flor, H, Birbaumer, N (2004). A placebo-controlled randomized crossover trial of the N-methyl-d-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesthesia and Analgesia 98, 408–413.CrossRefGoogle ScholarPubMed
Wiech, K, Preissl, H, Kiefer, T, Töpfner, S, Puali, P, Grillon, C, Birbaumer, N (2001). Prevention of phantom limb pain and cortical reorganization in the early phase after amputation in humans. Society for Neuroscience 27, 163–169.Google Scholar
Wing, J, Lelliott, P, Chaplin, RH (1999). Reliability and validity of HoNOS (multiple letters). Psychiatric Bulletin 23, 375.CrossRefGoogle Scholar
World Medical Association (2013). World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Journal of the American Medical Association 310, 2191–2194.CrossRefGoogle Scholar
Zdanys, K, Tampi, RR (2008). A systematic review of off-label uses of memantine for psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32, 1362–1374.CrossRefGoogle ScholarPubMed
Zierhut, KC, Schulte-Kemna, A, Kaufmann, J, Steiner, J, Bogerts, B, Schiltz, K (2013). Distinct structural alterations independently contributing to working memory deficits and symptomatology in paranoid schizophrenia. Cortex 49, 1063–1072.CrossRefGoogle ScholarPubMed
Zoccali, R, Muscatello, MR, Bruno, A, Cambria, R, Micò, U, Spina, E, Meduri, M (2007). The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophrenia Research 93, 109–116.CrossRefGoogle Scholar
Supplementary material: File

Veerman supplementary material S1

Supplementary Table

Download Veerman supplementary material S1(File)
File 44 KB
Supplementary material: File

Veerman supplementary material S2

Supplementary Table

Download Veerman supplementary material S2(File)
File 42 KB